TW202123978A - 抗癌劑暴露防止方法 - Google Patents
抗癌劑暴露防止方法 Download PDFInfo
- Publication number
- TW202123978A TW202123978A TW109139151A TW109139151A TW202123978A TW 202123978 A TW202123978 A TW 202123978A TW 109139151 A TW109139151 A TW 109139151A TW 109139151 A TW109139151 A TW 109139151A TW 202123978 A TW202123978 A TW 202123978A
- Authority
- TW
- Taiwan
- Prior art keywords
- hypochlorous acid
- solution
- anticancer agent
- test
- aqueous solution
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title claims abstract description 69
- 238000000034 method Methods 0.000 title claims abstract description 29
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 claims abstract description 61
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims abstract description 24
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims abstract description 22
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229960004397 cyclophosphamide Drugs 0.000 claims abstract description 16
- 229930012538 Paclitaxel Natural products 0.000 claims abstract description 15
- 229960001592 paclitaxel Drugs 0.000 claims abstract description 15
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims abstract description 15
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims abstract description 11
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims abstract description 11
- 229960004316 cisplatin Drugs 0.000 claims abstract description 11
- 229960002949 fluorouracil Drugs 0.000 claims abstract description 11
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims abstract description 11
- 229960005277 gemcitabine Drugs 0.000 claims abstract description 11
- 229960001428 mercaptopurine Drugs 0.000 claims abstract description 11
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims abstract description 11
- 229960001756 oxaliplatin Drugs 0.000 claims abstract description 11
- 229960004528 vincristine Drugs 0.000 claims abstract description 11
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims abstract description 11
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims abstract description 11
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229960002707 bendamustine Drugs 0.000 claims abstract description 10
- 229960004679 doxorubicin Drugs 0.000 claims abstract description 8
- 239000000243 solution Substances 0.000 claims description 69
- 239000007864 aqueous solution Substances 0.000 claims description 47
- 238000005507 spraying Methods 0.000 claims description 15
- 230000002265 prevention Effects 0.000 claims description 13
- 239000007921 spray Substances 0.000 claims description 8
- 239000003595 mist Substances 0.000 claims description 5
- 229940009456 adriamycin Drugs 0.000 claims description 4
- 231100000252 nontoxic Toxicity 0.000 claims description 4
- 230000003000 nontoxic effect Effects 0.000 claims description 4
- 238000012360 testing method Methods 0.000 description 63
- 238000000354 decomposition reaction Methods 0.000 description 52
- 239000007788 liquid Substances 0.000 description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 238000002360 preparation method Methods 0.000 description 20
- 239000000126 substance Substances 0.000 description 19
- 239000003814 drug Substances 0.000 description 18
- 239000008213 purified water Substances 0.000 description 16
- 229940079593 drug Drugs 0.000 description 13
- 238000005259 measurement Methods 0.000 description 13
- 238000012790 confirmation Methods 0.000 description 11
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 10
- 238000010998 test method Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000012488 sample solution Substances 0.000 description 9
- 229940041181 antineoplastic drug Drugs 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000011550 stock solution Substances 0.000 description 7
- 239000005708 Sodium hypochlorite Substances 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- 229940100198 alkylating agent Drugs 0.000 description 4
- 239000002168 alkylating agent Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 238000011056 performance test Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 239000003560 cancer drug Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 206010073310 Occupational exposures Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 230000007524 negative regulation of DNA replication Effects 0.000 description 1
- 230000021616 negative regulation of cell division Effects 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 231100000675 occupational exposure Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 239000011882 ultra-fine particle Substances 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A62—LIFE-SAVING; FIRE-FIGHTING
- A62D—CHEMICAL MEANS FOR EXTINGUISHING FIRES OR FOR COMBATING OR PROTECTING AGAINST HARMFUL CHEMICAL AGENTS; CHEMICAL MATERIALS FOR USE IN BREATHING APPARATUS
- A62D3/00—Processes for making harmful chemical substances harmless or less harmful, by effecting a chemical change in the substances
- A62D3/30—Processes for making harmful chemical substances harmless or less harmful, by effecting a chemical change in the substances by reacting with chemical agents
- A62D3/38—Processes for making harmful chemical substances harmless or less harmful, by effecting a chemical change in the substances by reacting with chemical agents by oxidation; by combustion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L9/00—Disinfection, sterilisation or deodorisation of air
- A61L9/01—Deodorant compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L9/00—Disinfection, sterilisation or deodorisation of air
- A61L9/14—Disinfection, sterilisation or deodorisation of air using sprayed or atomised substances including air-liquid contact processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2101/00—Chemical composition of materials used in disinfecting, sterilising or deodorising
- A61L2101/02—Inorganic materials
- A61L2101/06—Inorganic materials containing halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2209/00—Aspects relating to disinfection, sterilisation or deodorisation of air
- A61L2209/10—Apparatus features
- A61L2209/13—Dispensing or storing means for active compounds
- A61L2209/132—Piezo or ultrasonic elements for dispensing
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Business, Economics & Management (AREA)
- Emergency Management (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019-203722 | 2019-11-11 | ||
| JP2019203722 | 2019-11-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202123978A true TW202123978A (zh) | 2021-07-01 |
Family
ID=75912915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW109139151A TW202123978A (zh) | 2019-11-11 | 2020-11-10 | 抗癌劑暴露防止方法 |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JPWO2021095696A1 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220084109A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114728189A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202123978A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021095696A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS53125312A (en) | 1977-04-07 | 1978-11-01 | Kajima Corp | Method of placing underground wall |
| GB9323399D0 (en) * | 1993-11-12 | 1994-01-05 | Univ Newcastle Ventures Ltd | Pharmaceutical formulations |
| DE69840706D1 (de) * | 1997-11-11 | 2009-05-14 | Takara Bio Inc | Arzneimittel, speisen oder getränke mit physiologisch aktiven stoffen aus algen |
| US6092445A (en) | 1999-04-29 | 2000-07-25 | Skackelford; Jerry Lynn | Telescoping die holder |
| JP2003169842A (ja) * | 2001-12-04 | 2003-06-17 | Sony Corp | 次亜塩素酸水溶液による殺菌方法および殺菌装置 |
| MXPA04009412A (es) * | 2002-03-28 | 2005-12-12 | Oxis Int Inc | Metodos neuroprotectores, composiciones y metodos para seleccion de los mismos. |
| JP2006081802A (ja) * | 2004-09-17 | 2006-03-30 | Technomax:Kk | 次亜塩素酸含有水による悪臭物質収容施設の殺菌・消臭方法及びそれに用いる装置 |
| TW200714276A (en) * | 2005-10-12 | 2007-04-16 | Chiayi University | Method for producing anti-tumor compound, piceatannol |
| WO2010148004A1 (en) * | 2009-06-15 | 2010-12-23 | Oculus Innovative Sciences, Inc. | Solution containing hypochlorous acid and methods of using same |
| EP2558156B1 (en) * | 2010-04-14 | 2017-11-01 | Hypo-Stream Limited | Device for preparing dilute disinfectant solution |
| JP5613900B2 (ja) * | 2010-10-27 | 2014-10-29 | 学校法人 岩手医科大学 | 光触媒水性組成物及び該組成物を用いた抗がん剤分解法 |
| JP3166522U (ja) * | 2010-12-24 | 2011-03-10 | ナナイロ株式会社 | 除菌消臭用噴霧器 |
| JP6258600B2 (ja) | 2013-05-08 | 2018-01-10 | ベクトン・ディキンソン・アンド・カンパニーBecton, Dickinson And Company | 輸液チューブセットおよびその使用方法 |
| WO2014208428A1 (ja) * | 2013-06-25 | 2014-12-31 | 株式会社タムラテコ | 抗がん剤分解方法および抗がん剤分解装置 |
| JP2018516964A (ja) * | 2015-06-09 | 2018-06-28 | サン、ファーマ、アドバンスト、リサーチ、カンパニー、リミテッドSun Pharma Advanced Research Company Limited | 局所進行性または転移性である肝内もしくは肝外胆管または胆嚢のカルシノーマに罹患する患者を治療する方法 |
| KR102709765B1 (ko) | 2016-03-28 | 2024-09-26 | 어플라이드 머티어리얼스, 인코포레이티드 | 서셉터 지지부 |
| KR102329676B1 (ko) | 2017-05-17 | 2021-11-19 | 엘지전자 주식회사 | 스마트 비데 및 이를 포함하는 제어 시스템 |
| JP2020174900A (ja) * | 2019-04-18 | 2020-10-29 | 緒方 康夫 | 抗癌剤を分解するための薬剤および方法 |
-
2020
- 2020-11-09 JP JP2021556088A patent/JPWO2021095696A1/ja active Pending
- 2020-11-09 WO PCT/JP2020/041778 patent/WO2021095696A1/ja not_active Ceased
- 2020-11-09 KR KR1020227016126A patent/KR20220084109A/ko not_active Ceased
- 2020-11-09 CN CN202080078466.7A patent/CN114728189A/zh active Pending
- 2020-11-10 TW TW109139151A patent/TW202123978A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021095696A1 (ja) | 2021-05-20 |
| JPWO2021095696A1 (cg-RX-API-DMAC7.html) | 2021-05-20 |
| CN114728189A (zh) | 2022-07-08 |
| KR20220084109A (ko) | 2022-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | Nanocatalytic biofunctional MOF coating on titanium implants promotes osteoporotic bone regeneration through cooperative pro-osteoblastogenesis MSC reprogramming | |
| dos Santos Jr et al. | A new “silver-bullet” to treat caries in children–nano silver fluoride: a randomised clinical trial | |
| JP6771512B2 (ja) | 抗不安薬組成物、製剤および使用方法 | |
| Hadrup et al. | Toxicological risk assessment of elemental gold following oral exposure to sheets and nanoparticles–a review | |
| DE102005035472A1 (de) | Chemische Dialysatformulierungen auf Citratbasis | |
| WO2005016234A2 (en) | Compositions, methods, apparatuses, and systems for singlet oxygen delivery | |
| Hu et al. | Combinatorial low dose arsenic trioxide and cisplatin exacerbates autophagy via AMPK/STAT3 signaling on targeting head and neck cancer initiating cells | |
| CN110013478A (zh) | 用于抗肿瘤试剂施用的方法 | |
| TR201811221T4 (tr) | Dişi gastroparezi ile ilişkili semptomların tedavisi. | |
| CN105434351A (zh) | 一种复方醋酸氟轻松新型喷雾剂及其制备方法 | |
| Raza et al. | Review on harnessing silver nanoparticles for therapeutic innovations: A comprehensive review on medical applications, safety, and future directions | |
| CA2848895C (en) | Treatment of compartment syndrome | |
| WO2021095696A1 (ja) | 抗がん剤曝露防止方法 | |
| JP2020174900A (ja) | 抗癌剤を分解するための薬剤および方法 | |
| Lachenmeier | Antiseptic drugs and disinfectants | |
| US20110077572A1 (en) | Medical Equipment and Products using Chlorine, Hydrogen Peroxide, and Anti-Viral, Anti-Bacterial, Anti-Fungal, Agents, usage Method Improvements Dread Disease Cures, Remissions, and Anti-Infective Treatment Measures, Disease Treatment and Prevention System | |
| JP2024090489A (ja) | 抗がん剤分解液 | |
| González-Ventosa et al. | Measures to prevent the risks associated with exposure to cytostatic drugs in glaucoma filtering surgery | |
| JP2024064799A (ja) | 抗がん剤分解液及びこれを用いた抗がん剤分解方法 | |
| TW436287B (en) | Pharmaceutical composition for intramuscular administration comprising N-substituted benzamides, phenothiazines and their acid addition salts | |
| US11260110B2 (en) | Nanoparticles for the therapeutic treatment of radiation-induced skin ulcers | |
| JP2019210237A (ja) | 水素を含む加齢黄班変性治療用組成物 | |
| Lachenmeier | Side effects of antiseptic drugs and disinfectants with experience of the third year of COVID-19 | |
| Pitello et al. | Approaches for administering chemotherapy in the intensive care unit | |
| Davis et al. | Chemotherapy and hormonal therapy |